-
Product Insights
Likelihood of Approval Analysis for Eye Infections
Overview How likely is it that the drugs in Eye Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eye Infections Overview An eye infection is a disease caused by a...
-
Product Insights
Likelihood of Approval Analysis for Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that the drugs in Keratoconjunctivitis Sicca (Dry Eye) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Keratoconjunctivitis Sicca (Dry Eye) Overview Keratoconjunctivitis sicca (KCS), also called...
-
Product Insights
Likelihood of Approval Analysis for Ocular Pain (Eye Pain)
Overview How likely is it that the drugs in Ocular Pain (Eye Pain) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Pain (Eye Pain) Overview Ocular pain, commonly known as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Licaminlimab (OCS-02)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rebamipide in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebamipide in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebamipide in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Rebamipide (DWP-DN11)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenegermin in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Cenegermin (Oxervate)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OKYO-0101 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OKYO-0101 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OKYO-0101 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: OKYO-0101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALY-688 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALY-688 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALY-688 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: ALY-688 (ADP-355)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adipose Tissue Derived Mesenchymal...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...